Bidding War Ends as Inverness Plans to Acquire Biosite for $92.50 a Share | GenomeWeb
NEW YORK (GenomeWeb News) — Inverness Medical Innovations will buy Biosite after Beckman Coulter bowed out of the companies' protracted bidding war, Inverness said late yesterday on its Web site.
 
Under the purchase agreement, which comes after more than six weeks of offers, counteroffers, and negotiations, Inverness will pay $92.50 a share for 95 percent of Biosite's outstanding shares. Inverness already owns 5 percent.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.

Arizona is planning to sue Theranos for "deceptive acts" and misrepresentations of its "capabilities and operation."

If confirmed as Department of Health and Human Services Secretary, Tom Price says he will divest himself of certain holdings, according to Stat News.

Oliver Smithies, who won the Nobel Prize in 2007, has died, the New York Times reports.